The PBS subsidises alirocumab and evolocumab for patients with hypercholesterolaemia.
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment for hypercholesterolaemia under the National Health Act 1953, section 85 for patients with either:
- Evolocumab for familial homozygous, familial heterozygous hypercholesterolaemia or non-familial hypercholesterolaemia
- Alirocumab for familial heterozygous hypercholesterolaemia or non-familial hypercholesterolaemia.
Patients must be eligible for the PBS and meet the relevant restrictions criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing alirocumab and evolocumab.
Applying for initial treatment
Apply for initial authority approval to prescribe PBS subsidised alirocumab or evolocumab either:
Applying for initial grandfather treatment
Apply for initial grandfather authority approval to prescribe PBS subsidised alirocumab and evolocumab to treat hypercholesterolaemia either:
Applying for continuing treatment
Continuing treatment with alirocumab or evolocumab is Authority Required (Streamlined). It doesn’t need prior authority approval from us for listed quantities and repeats.
Call the PBS authority approvals line for further information.
Page last updated: 1 August 2021
This information was printed 7 October 2021 from https://www.servicesaustralia.gov.au/organisations/health-professionals/services/medicare/written-authority-required-drugs/drug-program-or-condition/hypercholesterolaemia. It may not include all of the relevant information on this topic. Please consider any relevant site notices at https://www.servicesaustralia.gov.au/individuals/site-notices when using this material.